Charles Schwab: TG Therapeutics TGTX Historial de posiciones en acciones
Comprado
Mantenidas
Vendido
| Trimestre | Valor de mercado | Estado | Acciones |
Cambio en la posición | Valor operado | Peso en el portafolio | Puesto en el portafolio | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | USD 86.1 M | Compra |
1,544,281
+231,178
| +18% | +USD 12.5 M | 0.01% | 883 |
|
|
2026
Q2 | USD 72.1 M | Compra |
1,313,103
+18,048
| +1% | +USD 739 k | 0.01% | 990 |
|
|
2026
Q1 | USD 43 M | Venta |
1,295,055
-16,634
| -1% | -USD 496 k | 0.01% | 1259 |
|
|
2025
Q4 | USD 39.1 M | Compra |
1,311,689
+1,532
| +0.1% | +USD 50 k | 0.01% | 1311 |
|
|
2025
Q3 | USD 47.3 M | Venta |
1,310,157
-6,339
| -0.5% | -USD 209 k | 0.01% | 1194 |
|
|
2025
Q2 | USD 47.4 M | Compra |
1,316,496
+53,559
| +4% | +USD 1.99 M | 0.01% | 1142 |
|
|
2025
Q1 | USD 49.8 M | Venta |
1,262,937
-6,576
| -0.5% | -USD 221 k | 0.01% | 1074 |
|
|
2024
Q4 | USD 38.2 M | Compra |
1,269,513
+84,904
| +7% | +USD 2.44 M | 0.01% | 1320 |
|
|
2024
Q3 | USD 27.7 M | Sin cambios |
1,184,609
| – | – | 0.01% | 1515 |
|
|
2024
Q2 | USD 20.9 M | Sin cambios |
1,176,670
| – | – | ﹤0.01% | 1655 |
|
|
2024
Q1 | USD 17.4 M | Compra |
1,145,569
+13,673
| +1% | +USD 218 k | ﹤0.01% | 1697 |
|
|
2023
Q4 | USD 19.3 M | Compra |
1,131,896
+19,214
| +2% | +USD 223 k | ﹤0.01% | 1617 |
|
|
2023
Q3 | USD 9.3 M | Compra |
1,112,682
+31,872
| +3% | +USD 444 k | ﹤0.01% | 1947 |
|
|
2023
Q2 | USD 26.8 M | Compra |
1,080,810
+35,058
| +3% | +USD 906 k | 0.01% | 1282 |
|
|
2023
Q1 | USD 15.7 M | Compra |
1,045,752
+27,445
| +3% | +USD 417 k | ﹤0.01% | 1636 |
|
|
2022
Q4 | USD 12 M | Compra |
1,018,307
+27,449
| +3% | +USD 199 k | ﹤0.01% | 1756 |
|
|
2022
Q3 | USD 5.87 M | Compra |
990,858
+49,186
| +5% | +USD 323 k | ﹤0.01% | 2129 |
|
|
2022
Q2 | USD 4 M | Venta |
941,672
-13,751
| -1% | -USD 85.9 k | ﹤0.01% | 2287 |
|
|
2022
Q1 | USD 9.09 M | Compra |
955,423
+17,029
| +2% | +USD 197 k | ﹤0.01% | 2009 |
|
|
2021
Q4 | USD 17.8 M | Compra |
938,394
+23,927
| +3% | +USD 621 k | 0.01% | 1671 |
|
|
2021
Q3 | USD 30.4 M | Compra |
914,467
+45,885
| +5% | +USD 1.42 M | 0.01% | 1215 |
|
|
2021
Q2 | USD 33.7 M | Compra |
868,582
+27,619
| +3% | +USD 1.08 M | 0.01% | 1160 |
|
|
2021
Q1 | USD 40.5 M | Compra |
840,963
+113,794
| +16% | +USD 5.47 M | 0.01% | 973 |
|
|
2020
Q4 | USD 37.8 M | Compra |
727,169
+34,116
| +5% | +USD 1.15 M | 0.02% | 961 |
|
|
2020
Q3 | USD 18.5 M | Compra |
693,053
+44,395
| +7% | +USD 1.02 M | 0.01% | 1252 |
|
|
2020
Q2 | USD 12.6 M | Compra |
648,658
+96,722
| +18% | +USD 1.56 M | 0.01% | 1492 |
|
|
2020
Q1 | USD 5.43 M | Compra |
551,936
+38,888
| +8% | +USD 491 k | ﹤0.01% | 1795 |
|
|
2019
Q4 | USD 5.7 M | Compra |
513,048
+45,399
| +10% | +USD 345 k | ﹤0.01% | 1956 |
|
|
2019
Q3 | USD 2.63 M | Compra |
467,649
+31,216
| +7% | +USD 218 k | ﹤0.01% | 2292 |
|
|
2019
Q2 | USD 3.78 M | Compra |
436,433
+47,585
| +12% | +USD 360 k | ﹤0.01% | 2110 |
|
|
2019
Q1 | USD 3.13 M | Compra |
388,848
+40,634
| +12% | +USD 220 k | ﹤0.01% | 2201 |
|
|
2018
Q4 | USD 1.43 M | Compra |
348,214
+18,567
| +6% | +USD 92.3 k | ﹤0.01% | 2430 |
|
|
2018
Q3 | USD 1.85 M | Compra |
329,647
+15,895
| +5% | +USD 182 k | ﹤0.01% | 2449 |
|
|
2018
Q2 | USD 4.13 M | Compra |
313,752
+45,578
| +17% | +USD 627 k | ﹤0.01% | 2101 |
|
|
2018
Q1 | USD 3.81 M | Compra |
268,174
+1,204
| +0.5% | +USD 15.4 k | ﹤0.01% | 2077 |
|
|
2017
Q4 | USD 2.19 M | Compra |
266,970
+23,485
| +10% | +USD 205 k | ﹤0.01% | 2274 |
|
|
2017
Q3 | USD 2.89 M | Compra |
243,485
+155,535
| +177% | +USD 1.77 M | ﹤0.01% | 2139 |
|
|
2017
Q2 | USD 884 k | Compra |
87,950
+15,900
| +22% | +USD 178 k | ﹤0.01% | 2498 |
|
|
2017
Q1 | USD 840 k | Venta |
72,050
-26,200
| -27% | -USD 188 k | ﹤0.01% | 2478 |
|
|
2016
Q4 | USD 457 k | Compra |
98,250
+39,200
| +66% | +USD 230 k | ﹤0.01% | 2689 |
|
|
2016
Q3 | USD 458 k | Sin cambios |
59,050
| – | – | ﹤0.01% | 2636 |
|
|
2016
Q2 | USD 358 k | Sin cambios |
59,050
| – | – | ﹤0.01% | 2715 |
|
|
2016
Q1 | USD 504 k | Sin cambios |
59,050
| – | – | ﹤0.01% | 2577 |
|
|
2015
Q4 | USD 705 k | Sin cambios |
59,050
| – | – | ﹤0.01% | 2502 |
|
|
2015
Q3 | USD 596 k | Compra |
59,050
+9,300
| +19% | +USD 139 k | ﹤0.01% | 2556 |
|
|
2015
Q2 | USD 826 k | Compra |
49,750
+8,650
| +21% | +USD 137 k | ﹤0.01% | 2504 |
|
|
2015
Q1 | USD 637 k | Compra |
41,100
+6,700
| +19% | +USD 101 k | ﹤0.01% | 2547 |
|
|
2014
Q4 | USD 545 k | Sin cambios |
34,400
| – | – | ﹤0.01% | 2590 |
|
|
2014
Q3 | USD 368 k | Sin cambios |
34,400
| – | – | ﹤0.01% | 2705 |
|
|
2014
Q2 | USD 324 k | Venta |
34,400
-15,400
| -31% | -USD 98.5 k | ﹤0.01% | 2824 |
|
|
2014
Q1 | USD 344 k | Sin cambios |
49,800
| – | – | ﹤0.01% | 2744 |
|
|
2013
Q4 | USD 195 k | Compra |
49,800
+31,600
| +174% | +USD 128 k | ﹤0.01% | 2959 |
|
|
2013
Q3 | USD 94 k | Sin cambios |
18,200
| – | – | ﹤0.01% | 3039 |
|
|
2013
Q2 | USD 121 k | Sin cambios |
18,200
| – | – | ﹤0.01% | 3009 |
|
Otros fondos que tienen TGTX en su portafolio
Posición de Charles Schwab en TGTX: resumen de T3 2026
Charles Schwab aumentó su participación en TG Therapeutics (TGTX) en 18% durante T3 2026, al comprar aproximadamente USD 12.5 M y elevar la posición a 1,544,281 acciones con un valor de USD 86.1 M. La posición representa 0.01% del portafolio y ocupa el puesto #883.
Charles Schwab reportó por primera vez una posición en TGTX en T2 2013 y desde entonces la ha mantenido en 54 trimestres. Al cierre de T3 2026, 455 fondos que sigue Wall St. Rank mantienen una posición en TGTX.
- Al cierre de T3 2026, Charles Schwab tenía 1,544,281 acciones de TG Therapeutics con un valor de USD 86.1 M.
- Charles Schwab compró 231,178 acciones de TG Therapeutics en T3 2026, por un monto estimado de USD 12.5 M.
- TG Therapeutics representó el 0.01% del portafolio de Charles Schwab en T3 2026 y fue su posición número 883.
- Charles Schwab reportó por primera vez una posición en TG Therapeutics en T2 2013 y desde entonces la ha mantenido en 54 trimestres.
- Al cierre de T3 2026, 455 fondos que sigue Wall St. Rank tenían TG Therapeutics en su portafolio.
Según el informe 13F de Charles Schwab correspondiente a T3 2026, presentado el 16 nov 2026.